Repurposing public sarcoma multi-omics for neoantigen discovery

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background : Soft tissue sarcomas, particularly Complex Karyotype Sarcomas (CKS), are characterized as "immunologically cold" malignancies driven by structural instability rather than a high tumor mutational burden (TMB). Public “legacy” cohorts are a useful resource to uncover immunotherapy biomarkers. This study used the Whole Exome Sequencing (WES) and RNA-sequencing of CKS patients, to overcome technical limitations and to identify and prioritize neoantigens. Methods : The systematic immunogenomic reanalysis was performed on a landmark cohort of CKS patients (Kim et al., 2018) with a custom bioinformatics workflow which was developed to uncover interpretable immunogenomic signals. This approach consisted of: (1) defining a quality-controlled "callable territory" and normalizing TMB metrics respectively; (2) utilizing RNA-seq not only for expression filtering but as an orthogonal validation check for variant transcription and to distinguish functional amplifications from technical depth artifacts; and (3) applying a multi-modal epitope prediction pipeline to identify and prioritize high-affinity neoantigens derived from both somatic SNVs indels and expressed gene fusions. Results : The reanalysis shows that standard genome-wide metrics frequently underestimated the immunogenic potential. Normalizing the TMB refined the identification of hypermutated and microsatellite instability-like phenotypes. Furthermore, integration of transcriptomic data facilitated the recovery of actionable targets in "low-TMB" tumors. A subset of fusion-derived peptides demonstrated predicted binding affinities competitive with SNV-derived candidates. Conclusion : This study illustrates that technically constrained multi-omic datasets can be systematically re-analyzed to identify potential therapeutic targets. These data argue for looking beyond aggregate biomarkers; patient-specific, expressed neoepitopes may exist even in sarcomas typically described as immunologically “cold”.

Article activity feed